FindTrial
Sign In

Retrospective Clinical Study about the Treatment and Prognosis of Patients with Diffuse Large B-cell Lymphoma

Outcomes in Refractory Diffuse Large B-cell Lymphoma: Results from a Multi-center Real-world Study in China

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000041138
Enrollment
Unknown
Registered
2020-12-19
Start date
2018-01-18
Completion date
Unknown
Last updated
2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B-cell Lymphoma

Interventions

Case series:Nil

Sponsors

Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. According to the national comprehensive cancer network (NCCN) clinical practice guidelines for non Hodgkin's lymphoma (1st edition, 2017), patients with histologically confirmed diffuse large B-cell lymphoma; 2. Patients with complete medical history: they were followed up for at least 3 months after receiving at least one standard treatment.

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

MeasureTime frame
Overall Response Rate;—

Secondary

MeasureTime frame
Overall Survival;Progression-free Survival;—

Countries

China

Contacts

Public ContactZhao Weili

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

zhao.weili@yahoo.com+86 13512112076

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026